Compare Axon Enterprise Inc (AXON) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Illumina, Inc. — how do they compare? Axon Enterprise Inc trades at $600.01 (market cap $51.69B), while Illumina, Inc. trades at $191.5 (market cap $29.12B). The key difference: Axon Enterprise Inc is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| AXON | ILMN | |
|---|---|---|
Market Cap | $51.69B | $29.12B |
Sector | Technology | Health |
52-Week High | $791.62 | $205.10 |
52-Week Low | $345.94 | $91.00 |
Enterprise Value | $52.83B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXON trades at $599.78, up 0.58% on the day, consolidating after a strong uptrend. The stock shows bullish technical signals with support near $616 and resistance at $649. Fundamentally, Q2 2026 revenue grew 35% year-over-year to $904 million, marking the tenth consecutive quarter of growth above 30%, with a net income margin of 6.19%. Analyst consensus is strongly bullish with an $685 price target, though valuation multiples remain elevated.
The outlook is positive given robust revenue growth and AI-driven expansion, but the high P/E of 265 presents a significant risk. Investors face a trade-off between strong operational execution and demanding valuations. Near-term catalysts include Q3 2026 earnings and continued execution on the $15.1B future contracted bookings pipeline.
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
